To allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages.
Summary
What This Bill Does
The bill provides temporary importation of prescription drugs Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C and requires 506C–2. Marginally competitive drug markets If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an applicable drug, the Secretary— shall treat such. It relies on definition changes, reporting requirements, compliance mandates, and appropriations. The main policy areas are Healthcare Consumers, Foreign Policy, and Healthcare.
Who Benefits and How
Patients and health care consumers affected by the bill could face lower compliance burdens, Foreign businesses and cross-border trade participants affected by the bill could face lower compliance burdens, and Public beneficiaries or protected communities affected by the clause could see lower costs.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Patients and health care consumers affected by the bill could lose revenue opportunities, and Foreign businesses and cross-border trade participants affected by the bill could lose revenue opportunities.
Key Provisions
- Provides temporary importation of prescription drugs Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
- Requires 506C–2. Marginally competitive drug markets If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an applicable drug, the Secretary— shall treat such...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides temporary importation of prescription drugs Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C and requires 506C–2. Marginally competitive drug markets If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an applicable drug, the Secretary— shall treat such.
Key Policy Areas
Healthcare Consumers, Foreign Policy, Healthcare
Primary Purpose
The bill provides temporary importation of prescription drugs Section 506C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C and requires 506C–2. Marginally competitive drug markets If the Secretary determines under subsection (b) that a marginally competitive market exists with respect to an applicable drug, the Secretary— shall treat such.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
- Foreign businesses and cross-border trade participants affected by the bill
- Public beneficiaries or protected communities affected by the clause
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Patients and health care consumers affected by the bill
- Foreign businesses and cross-border trade participants affected by the bill
- Public beneficiaries or protected communities affected by the clause
Sponsors
Legislative Progress
IntroducedMs. Klobuchar (for herself, Mr. Lee, Mr. Durbin, and Mr. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology